Adicet Bio (ACET)
(Real Time Quote from BATS)
$1.44 USD
-0.07 (-4.64%)
Updated Aug 2, 2024 02:38 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Adicet Bio, Inc. [ACET]
Reports for Purchase
Showing records 21 - 40 ( 108 total )
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expands to II via Lupus Nephritis; MCL New Focus
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Expansion, Persistence, and Pharmacodynamic Profile Data From Phase 1 Study Highlighted at ASH 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Weekend Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; ADI-001 Phase 1 Update Expected 2H24; Evaluating Pivotal Phase 2 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials, ADI-001 Jumps After the CAR(-T); ADI-270 Next up
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- EORTC-NCI-AACR 2023 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; ADI-001 Clinical Update Expected in 2H24; IND Filing for ADI-925 Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ADI-001 to Enter Registration-Directed Ph 2 in CAR-T r/r LBCL
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Impressive Updated Phase 1 Data for ADI-001 in r/r NHL; DL4 Selected as RP2D; Pivotal Phase 2 Study Could Begin 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ADI-001 Data Update: Focus Remains on Significant Post CAR-T Setting
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Day 3 of ASGCT 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preclinical Data Announced For ADI-270
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; ADI-001 Updates Expected This Quarter, Pivotal Trial Could Start in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Adicet Bio, Inc.
Industry: Medical - Biomedical and Genetics
ASGCT 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D